ArticleBMC cancer2023

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non-small cell lung cancer.

Chun-Yao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.